NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · SMALL CAP
Clearpoint Neuro, Inc. CLPT
16 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$37.0M
▲ 17.8% vs FY2024
EPS · FY25
$-0.90
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-95.6%
Net margin · FY25
-69.1%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 37.0M
Revenue, FY2025 · full 16-year series below
Revenue
Net income
The company lost 69 cents on every revenue dollar this year.
Per share
USD -0.90
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-95.6%
Return on equity, FY2025
ROE
Operating margin-65.4%
Net margin-69.1%
Return on assets-37.3%
Each USD of equity lost 96 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+23.6% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+21.6%
+23.6%
+23.2%
+19.2%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.03B
Shares outstanding, FY2025
Change, 5 years+72.3%
Change, 10 years—
The share count grew 72% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 97.7M
total assets, end of FY2025
Total assetsUSD 97.7M
EquityUSD 28.0M
CashUSD 45.9M
Gross debtUSD 49.1M
Net debtUSD 3.2M
Current ratio5.91×
Net debt stands at 11% of equity.
History
16 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
·
·
·
·
·
0.0
0.0
0.0
·
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.90
−0.70
−0.90
−0.68
−0.69
−0.43
−0.42
−0.56
−0.93
−2.93
−4.48
−0.08
−0.12
−0.15
−0.52
−1.40
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−95.6
−81.2
−76.1
−38.4
−56.3
−194.8
−181.8
−168.0
−282.6
·
·
·
·
·
·
·
Shares out B
0.03
0.03
0.02
0.02
0.02
0.02
0.02
0.01
0.01
0.00
0.00
0.07
0.06
0.05
0.02
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
52 of 52
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed